Mylan Q1 Mixed; Abiomed, Mallinckrodt, Zoetis Beat

By | May 5, 2015

Scalper1 News

Generic-drug giant Mylan delivered a mixed first-quarter report late Tuesday after three other top-rated medical stocks issued more positive reports earlier in the day. Its shares slipped a fraction in after-hours trading. Mylan’s (MYL) profit rose 6% over the year-earlier quarter to 70 cents a share, beating analysts’ consensus by a penny, according to Thomson Reuters. Sales increased 9% to $1.87 billion, missing Wall Street’s number by around Scalper1 News

Scalper1 News